21 October 2026
Published reports on thymosin alpha-1
Download PDF
In vitro, clinical, and review reports on thymosin alpha-1, each with study type and a stated limitation. Observations only; no health claims.
This briefing records what published papers reported on thymosin alpha-1. It does not interpret those reports as effects in people or animals outside the cited settings.
In vitro. A 2026 cell-culture study reported that thymosin α1 alone was associated with a moderate increase in CD8+ T-cell proliferation and activation. With CD3/CD28 stimulation, the report described a further rise in the proliferation index and in CD69, CD25, and HLA-DR expression, and higher secretion of IL-2, IFN-γ, TNF-α, and IL-10. After repeated CD3/CD28 stimulation, the same report described lower PD-1, TIM-3, and LAG-3. Limitation: culture model only; the abstract states that in vivo validation is still needed.
Clinical. An open-label randomized trial (2026) enrolled 73 patients with HBV-related acute-on-chronic liver failure (35 versus 38). The report described higher 90-day transplant-free survival in the thymosin α1 arm than in the comparator arm, lower Treg and CD226low/− Treg frequencies at weeks 4–8, and a moderated late-stage inflammatory response. Limitation: open-label design, one disease setting, and a modest sample; marker and outcome associations are not evidence of a general effect.
Review. A 2025 narrative review summarized literature linking thymosin alpha-1 with T-cell differentiation, thymic output, dendritic-cell and macrophage activity, vaccine response in older adults, and immunosenescence, and stated that long-term efficacy and safety in geriatrics remain to be established. Limitation: not new primary data; preclinical and clinical sources are mixed, and no single outcome is established.
Sources
- Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro (2026). DOI: 10.31557/APJCP.2026.27.6.2089. https://pubmed.ncbi.nlm.nih.gov/42345155/ - Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance (2026). DOI: 10.1080/08923973.2026.2641686. https://pubmed.ncbi.nlm.nih.gov/41887933/ - Aging and Thymosin Alpha-1 (2025). DOI: 10.3390/ijms262311470. https://pubmed.ncbi.nlm.nih.gov/41373628/
More briefings
- Survodutide Dual Agonist: Preclinical and Clinical EvidenceThe open-catalog entry for survodutide describes a synthetic acylated 29-amino-acid peptide dual agonist of glucagon and GLP-1 receptors supplied as high-purity lyophilized powder for laboratory metabolic research. Randomised trials report
- Dulaglutide: GLP-1 Receptor Agonist in Metabolic CareDulaglutide is a recombinant Fc-fusion GLP-1 receptor agonist engineered for once-weekly administration in laboratory and clinical metabolic research. Randomised trials report glycaemic improvements, cardiovascular risk reduction and modest
- Cagrilintide-Semaglutide Mixture: Open-Catalog Context and Metabolic Trial EvidenceThe open-catalog cagrilintide-semaglutide mixture supplies a research pairing of an amylin receptor agonist and GLP-1 receptor agonist for laboratory metabolic studies. Randomised trials of co-administration report enhanced weight loss (13–
All information and products discussed are for laboratory and research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.